1	Earnings	NNS	12	nsubjpass
2	for	IN	1	prep
3	most	JJS	2	pobj
4	of	IN	3	prep
5	the	DT	6	det
6	nation	NN	10	poss
7	's	POS	6	possessive
8	major	JJ	10	amod
9	pharmaceutical	JJ	10	amod
10	makers	NNS	4	pobj
11	are	VBP	12	auxpass
12	believed	VBN	0	root
13	to	TO	15	aux
14	have	VB	15	aux
15	moved	VBN	12	xcomp
16	ahead	RB	15	advmod
17	briskly	RB	15	advmod
18	in	IN	15	prep
19	the	DT	21	det
20	third	JJ	21	amod
21	quarter	NN	18	pobj
22	,	,	15	punct
23	as	IN	31	mark
24	companies	NNS	31	nsubj
25	with	IN	24	prep
26	newer	JJR	30	amod
27	,	,	30	punct
28	big-selling	JJ	30	amod
29	prescription	NN	30	nn
30	drugs	NNS	25	pobj
31	fared	VBD	15	advcl
32	especially	RB	33	advmod
33	well	RB	31	advmod
34	.	.	12	punct

1	For	IN	16	prep
2	the	DT	5	det
3	third	JJ	5	amod
4	consecutive	JJ	5	amod
5	quarter	NN	1	pobj
6	,	,	16	punct
7	however	RB	16	advmod
8	,	,	16	punct
9	most	JJS	16	nsubjpass
10	of	IN	9	prep
11	the	DT	12	det
12	companies	NNS	14	poss
13	'	POS	12	possessive
14	revenues	NNS	10	pobj
15	were	VBD	16	auxpass
16	battered	VBN	0	root
17	by	IN	16	prep
18	adverse	JJ	20	amod
19	foreign-currency	NN	20	nn
20	translations	NNS	17	pobj
21	as	IN	16	prep
22	a	DT	23	det
23	result	NN	21	pobj
24	of	IN	23	prep
25	the	DT	27	det
26	strong	JJ	27	amod
27	dollar	NN	24	pobj
28	abroad	RB	27	advmod
29	.	.	16	punct

1	Analysts	NNS	2	nsubj
2	said	VBD	0	root
3	that	IN	25	complm
4	Merck	NNP	25	nsubj
5	&	CC	4	cc
6	Co.	NNP	4	conj
7	,	,	4	punct
8	Eli	NNP	9	nn
9	Lilly	NNP	4	conj
10	&	CC	9	cc
11	Co.	NNP	9	conj
12	,	,	4	punct
13	Warner-Lambert	NNP	14	nn
14	Co.	NNP	4	conj
15	and	CC	4	cc
16	the	DT	19	det
17	Squibb	NNP	18	nn
18	Corp.	NNP	19	nn
19	unit	NN	4	conj
20	of	IN	19	prep
21	Bristol-Myers	NNP	22	nn
22	Squibb	NNP	23	nn
23	Co.	NNP	20	pobj
24	all	DT	25	dep
25	benefited	VBD	2	ccomp
26	from	IN	25	prep
27	strong	JJ	28	amod
28	sales	NNS	26	pobj
29	of	IN	28	prep
30	relatively	RB	31	advmod
31	new	JJ	34	amod
32	,	,	34	punct
33	higher-priced	JJ	34	amod
34	medicines	NNS	29	pobj
35	that	WDT	36	nsubj
36	provide	VBP	34	rcmod
37	wide	JJ	39	amod
38	profit	NN	39	nn
39	margins	NNS	36	dobj
40	.	.	2	punct

1	Less	RBR	2	advmod
2	robust	JJ	3	amod
3	earnings	NNS	11	nsubjpass
4	at	IN	3	prep
5	Pfizer	NNP	6	nn
6	Inc.	NNP	4	pobj
7	and	CC	6	cc
8	Upjohn	NNP	9	nn
9	Co.	NNP	6	conj
10	were	VBD	11	auxpass
11	attributed	VBN	0	root
12	to	TO	11	prep
13	those	DT	14	det
14	companies	NNS	17	poss
15	'	POS	14	possessive
16	older	JJR	17	amod
17	products	NNS	12	pobj
18	,	,	17	punct
19	many	JJ	22	nsubj
20	of	IN	19	prep
21	which	WDT	20	pobj
22	face	VBP	17	rcmod
23	stiffening	JJ	24	amod
24	competition	NN	22	dobj
25	from	IN	24	prep
26	generic	JJ	27	amod
27	drugs	NNS	25	pobj
28	and	CC	27	cc
29	other	JJ	30	amod
30	medicines	NNS	27	conj
31	.	.	11	punct

1	Joseph	NNP	2	nn
2	Riccardo	NNP	13	nsubj
3	,	,	2	punct
4	an	DT	5	det
5	analyst	NN	2	appos
6	with	IN	5	prep
7	Bear	NNP	6	pobj
8	,	,	7	punct
9	Stearns	NNP	7	conj
10	&	CC	7	cc
11	Co.	NNP	7	conj
12	,	,	2	punct
13	said	VBD	0	root
14	that	IN	24	complm
15	over	IN	24	prep
16	the	DT	19	det
17	past	JJ	19	amod
18	few	JJ	19	amod
19	years	NNS	15	pobj
20	most	JJS	22	amod
21	drug	NN	22	nn
22	makers	NNS	24	nsubj
23	have	VBP	24	aux
24	shed	VBN	13	ccomp
25	their	PRP$	27	poss
26	slow-growing	JJ	27	amod
27	businesses	NNS	24	dobj
28	and	CC	24	cc
29	instituted	VBN	24	conj
30	other	JJ	32	amod
31	cost	NN	32	nn
32	savings	NNS	29	dobj
33	,	,	32	punct
34	such	JJ	35	mwe
35	as	IN	32	prep
36	consolidating	VBG	35	pcomp
37	manufacturing	NN	38	nn
38	plants	NNS	36	dobj
39	and	CC	38	cc
40	administrative	JJ	41	amod
41	staffs	NNS	38	conj
42	.	.	13	punct

1	As	IN	10	prep
2	a	DT	3	det
3	result	NN	1	pobj
4	,	,	10	punct
5	``	``	10	punct
6	major	JJ	8	amod
7	new	JJ	8	amod
8	products	NNS	10	nsubj
9	are	VBP	10	aux
10	having	VBG	26	ccomp
11	significant	JJ	12	amod
12	impact	NN	10	dobj
13	,	,	10	punct
14	even	RB	15	advmod
15	on	IN	10	prep
16	a	DT	17	det
17	company	NN	15	pobj
18	with	IN	17	prep
19	very	RB	20	advmod
20	large	JJ	21	amod
21	revenues	NNS	18	pobj
22	,	,	26	punct
23	''	''	26	punct
24	Mr.	NNP	25	nn
25	Riccardo	NNP	26	nsubj
26	said	VBD	0	root
27	.	.	26	punct

1	Analysts	NNS	2	nsubj
2	said	VBD	0	root
3	profit	NN	18	nsubjpass
4	for	IN	3	prep
5	the	DT	11	det
6	dozen	NN	11	num
7	or	CC	6	cc
8	so	RB	6	conj
9	big	JJ	11	amod
10	drug	NN	11	nn
11	makers	NNS	4	pobj
12	,	,	11	punct
13	as	IN	11	prep
14	a	DT	15	det
15	group	NN	13	pobj
16	,	,	11	punct
17	is	VBZ	18	auxpass
18	estimated	VBN	2	ccomp
19	to	TO	21	aux
20	have	VB	21	aux
21	climbed	VBN	18	xcomp
22	between	IN	27	quantmod
23	11	CD	27	number
24	%	NN	27	dep
25	and	CC	27	cc
26	14	CD	27	conj
27	%	NN	21	dobj
28	.	.	2	punct

1	While	IN	5	mark
2	that	DT	5	nsubj
3	's	VBZ	5	cop
4	not	RB	5	neg
5	spectacular	JJ	16	advcl
6	,	,	16	punct
7	Neil	NNP	8	nn
8	Sweig	NNP	16	nsubj
9	,	,	8	punct
10	an	DT	11	det
11	analyst	NN	8	appos
12	with	IN	11	prep
13	Prudential	NNP	14	nn
14	Bache	NNP	12	pobj
15	,	,	8	punct
16	said	VBD	0	root
17	that	IN	24	complm
18	the	DT	19	det
19	rate	NN	24	nsubj
20	of	IN	19	prep
21	growth	NN	20	pobj
22	will	MD	24	aux
23	``	``	24	punct
24	look	VB	16	ccomp
25	especially	RB	26	advmod
26	good	JJ	24	acomp
27	as	IN	28	mark
28	compared	VBN	26	ccomp
29	to	TO	28	prep
30	other	JJ	31	amod
31	companies	NNS	29	pobj
32	if	IN	35	mark
33	the	DT	34	det
34	economy	NN	35	nsubj
35	turns	VBZ	24	advcl
36	downward	RB	35	advmod
37	.	.	16	punct
38	''	''	16	punct

1	Mr.	NNP	2	nn
2	Sweig	NNP	3	nsubj
3	estimated	VBD	0	root
4	that	IN	11	complm
5	Merck	NNP	7	poss
6	's	POS	5	possessive
7	profit	NN	11	nsubj
8	for	IN	7	prep
9	the	DT	10	det
10	quarter	NN	8	pobj
11	rose	VBD	3	ccomp
12	by	IN	11	prep
13	about	RB	14	quantmod
14	22	CD	15	num
15	%	NN	12	pobj
16	,	,	11	punct
17	propelled	VBN	11	dep
18	by	IN	17	prep
19	sales	NNS	18	pobj
20	of	IN	19	prep
21	its	PRP$	22	poss
22	line-up	NN	20	pobj
23	of	IN	22	prep
24	fast-growing	JJ	26	amod
25	prescription	NN	26	nn
26	drugs	NNS	23	pobj
27	,	,	26	punct
28	including	VBG	26	prep
29	its	PRP$	31	poss
30	anti-cholesterol	JJ	31	amod
31	drug	NN	28	pobj
32	,	,	31	punct
33	Mevacor	NNP	31	appos
34	;	:	31	punct
35	a	DT	39	det
36	high	JJ	38	amod
37	blood	NN	38	nn
38	pressure	NN	39	nn
39	medicine	NN	31	conj
40	,	,	39	punct
41	Vasotec	NNP	39	appos
42	;	:	31	punct
43	Primaxin	NNP	31	conj
44	,	,	43	punct
45	an	DT	46	det
46	antibiotic	NN	43	appos
47	,	,	31	punct
48	and	CC	31	cc
49	Pepcid	NNP	31	conj
50	,	,	49	punct
51	an	DT	53	det
52	anti-ulcer	JJ	53	amod
53	medication	NN	49	appos
54	.	.	3	punct

1	Profit	NN	2	nsubj
2	climbed	VBD	28	ccomp
3	even	RB	9	advmod
4	though	IN	9	dep
5	Merck	NNP	7	poss
6	's	POS	5	possessive
7	sales	NNS	9	nsubjpass
8	were	VBD	9	auxpass
9	reduced	VBN	2	ccomp
10	by	IN	9	prep
11	``	``	10	punct
12	one	CD	14	number
13	to	TO	14	dep
14	three	CD	16	num
15	percentage	NN	16	nn
16	points	NNS	10	pobj
17	''	''	10	punct
18	as	IN	9	prep
19	a	DT	20	det
20	result	NN	18	pobj
21	of	IN	20	prep
22	the	DT	24	det
23	strong	JJ	24	amod
24	dollar	NN	21	pobj
25	,	,	28	punct
26	Mr.	NNP	27	nn
27	Sweig	NNP	28	nsubj
28	said	VBD	0	root
29	.	.	28	punct

1	In	IN	9	prep
2	the	DT	4	det
3	third	JJ	4	amod
4	quarter	NN	1	pobj
5	of	IN	4	prep
6	1988	CD	5	pobj
7	,	,	9	punct
8	Merck	NNP	9	nsubj
9	earned	VBD	0	root
10	$	$	9	dobj
11	311.8	CD	10	number
12	million	CD	10	number
13	,	,	10	punct
14	or	CC	10	cc
15	79	CD	16	num
16	cents	NNS	10	conj
17	a	DT	18	det
18	share	NN	16	npadvmod
19	.	.	9	punct

1	In	IN	9	prep
2	Rahway	NNP	1	pobj
3	,	,	2	punct
4	N.J.	NNP	2	appos
5	,	,	2	punct
6	a	DT	8	det
7	Merck	NNP	8	nn
8	spokesman	NN	9	nsubj
9	said	VBD	0	root
10	the	DT	11	det
11	company	NN	14	nsubj
12	does	VBZ	14	aux
13	n't	RB	14	neg
14	make	VB	9	ccomp
15	earnings	NN	16	nn
16	projections	NNS	14	dobj
17	.	.	9	punct

1	Mr.	NNP	2	nn
2	Sweig	NNP	3	nsubj
3	said	VBD	0	root
4	he	PRP	5	nsubj
5	estimated	VBD	3	ccomp
6	that	IN	13	complm
7	Lilly	NNP	9	poss
8	's	POS	7	possessive
9	earnings	NNS	13	nsubj
10	for	IN	9	prep
11	the	DT	12	det
12	quarter	NN	10	pobj
13	jumped	VBD	5	ccomp
14	about	RB	16	advmod
15	20	CD	16	num
16	%	NN	13	dobj
17	,	,	13	punct
18	largely	RB	20	advmod
19	because	IN	20	mwe
20	of	IN	13	prep
21	the	DT	22	det
22	performance	NN	20	pobj
23	of	IN	22	prep
24	its	PRP$	27	poss
25	new	JJ	27	amod
26	anti-depressant	NN	27	nn
27	Prozac	NNP	23	pobj
28	.	.	3	punct

1	The	DT	2	det
2	drug	NN	9	nsubjpass
3	,	,	2	punct
4	introduced	VBD	2	partmod
5	last	JJ	6	amod
6	year	NN	4	tmod
7	,	,	2	punct
8	is	VBZ	9	auxpass
9	expected	VBN	0	root
10	to	TO	11	aux
11	generate	VB	9	xcomp
12	sales	NNS	11	dobj
13	of	IN	12	prep
14	about	RB	15	quantmod
15	$	$	13	pobj
16	300	CD	15	number
17	million	CD	15	number
18	this	DT	19	det
19	year	NN	11	tmod
20	.	.	9	punct

1	``	``	15	punct
2	It	PRP	4	nsubj
3	's	VBZ	4	aux
4	turning	VBG	15	ccomp
5	out	RP	4	prt
6	to	TO	10	aux
7	be	VB	10	cop
8	a	DT	10	det
9	real	JJ	10	amod
10	blockbuster	NN	4	xcomp
11	,	,	15	punct
12	''	''	15	punct
13	Mr.	NNP	14	nn
14	Sweig	NNP	15	nsubj
15	said	VBD	0	root
16	.	.	15	punct

1	In	IN	9	prep
2	last	JJ	3	amod
3	year	NN	6	poss
4	's	POS	3	possessive
5	third	JJ	6	amod
6	quarter	NN	1	pobj
7	,	,	9	punct
8	Lilly	NNP	9	nsubj
9	earned	VBD	0	root
10	$	$	9	dobj
11	171.4	CD	10	number
12	million	CD	10	number
13	,	,	10	punct
14	or	CC	10	cc
15	$	$	10	conj
16	1.20	CD	15	num
17	a	DT	18	det
18	share	NN	15	npadvmod
19	.	.	9	punct

1	In	IN	5	prep
2	Indianapolis	NNP	1	pobj
3	,	,	5	punct
4	Lilly	NNP	5	nsubj
5	declined	VBD	0	root
6	comment	NN	5	dobj
7	.	.	5	punct

1	Several	JJ	2	amod
2	analysts	NNS	3	nsubj
3	said	VBD	0	root
4	they	PRP	5	nsubj
5	expected	VBD	3	ccomp
6	Warner-Lambert	NNP	8	poss
7	's	POS	6	possessive
8	profit	NN	11	nsubj
9	also	RB	11	advmod
10	to	TO	11	aux
11	increase	VB	5	xcomp
12	by	IN	11	prep
13	more	JJR	14	mwe
14	than	IN	15	quantmod
15	20	CD	16	num
16	%	NN	12	pobj
17	from	IN	11	prep
18	$	$	17	pobj
19	87.7	CD	18	number
20	million	CD	18	number
21	,	,	18	punct
22	or	CC	18	cc
23	$	$	18	conj
24	1.25	CD	23	num
25	a	DT	26	det
26	share	NN	23	npadvmod
27	,	,	18	punct
28	it	PRP	29	nsubj
29	reported	VBD	18	rcmod
30	in	IN	29	prep
31	the	DT	33	det
32	like	JJ	33	amod
33	period	NN	30	pobj
34	last	JJ	35	amod
35	year	NN	33	tmod
36	.	.	3	punct

1	The	DT	2	det
2	company	NN	4	nsubjpass
3	is	VBZ	4	auxpass
4	praised	VBN	0	root
5	by	IN	4	prep
6	analysts	NNS	5	pobj
7	for	IN	4	prep
8	sharply	RB	9	advmod
9	lowering	VBG	7	pcomp
10	its	PRP$	11	poss
11	costs	NNS	9	dobj
12	in	IN	9	prep
13	recent	JJ	14	amod
14	years	NNS	12	pobj
15	and	CC	9	cc
16	shedding	VBG	9	conj
17	numerous	JJ	18	amod
18	companies	NNS	16	dobj
19	with	IN	18	prep
20	low	JJ	22	amod
21	profit	NN	22	nn
22	margins	NNS	19	pobj
23	.	.	4	punct

1	The	DT	2	det
2	company	NN	5	poss
3	's	POS	2	possessive
4	lean	JJ	5	amod
5	operation	NN	10	nsubj
6	,	,	8	punct
7	analysts	NNS	8	nsubj
8	said	VBD	10	parataxis
9	,	,	8	punct
10	allowed	VBD	0	root
11	sharp-rising	JJ	12	amod
12	sales	NNS	21	nsubj
13	from	IN	12	prep
14	its	PRP$	16	poss
15	cholesterol	NN	16	nn
16	drug	NN	13	pobj
17	,	,	16	punct
18	Lopid	NNP	16	appos
19	,	,	16	punct
20	to	TO	21	aux
21	power	VB	10	xcomp
22	earnings	NNS	23	nn
23	growth	NN	21	dobj
24	.	.	10	punct

1	Lopid	NNP	2	nn
2	sales	NNS	4	nsubjpass
3	are	VBP	4	auxpass
4	expected	VBN	0	root
5	to	TO	8	aux
6	be	VB	8	cop
7	about	RB	8	quantmod
8	$	$	4	xcomp
9	300	CD	8	number
10	million	CD	8	number
11	this	DT	12	det
12	year	NN	8	tmod
13	,	,	8	punct
14	up	RB	8	advmod
15	from	IN	14	prep
16	$	$	15	pobj
17	190	CD	16	number
18	million	CD	16	number
19	in	IN	15	prep
20	1988	CD	19	pobj
21	.	.	4	punct

1	In	IN	12	prep
2	Morris	NNP	3	nn
3	Plains	NNP	1	pobj
4	,	,	3	punct
5	N.J.	NNP	3	appos
6	,	,	3	punct
7	a	DT	8	det
8	spokesman	NN	12	nsubj
9	for	IN	8	prep
10	the	DT	11	det
11	company	NN	9	pobj
12	said	VBD	0	root
13	the	DT	14	det
14	analysts	NNS	16	poss
15	'	POS	14	possessive
16	projections	NNS	17	nsubj
17	are	VBP	12	ccomp
18	``	``	17	punct
19	in	IN	17	prep
20	the	DT	21	det
21	ballpark	NN	19	pobj
22	.	.	12	punct
23	''	''	12	punct

1	Squibb	NNP	3	poss
2	's	POS	1	possessive
3	profit	NN	36	nsubj
4	,	,	36	punct
5	estimated	VBN	36	partmod
6	by	IN	5	prep
7	analysts	NNS	6	pobj
8	to	TO	9	aux
9	be	VB	5	xcomp
10	about	RB	11	quantmod
11	18	CD	12	num
12	%	NN	13	npadvmod
13	above	IN	9	prep
14	the	DT	15	det
15	$	$	13	pobj
16	123	CD	15	number
17	million	CD	15	number
18	,	,	15	punct
19	or	CC	15	cc
20	$	$	15	conj
21	1.25	CD	20	num
22	a	DT	23	det
23	share	NN	20	npadvmod
24	,	,	15	punct
25	it	PRP	26	nsubj
26	earned	VBD	15	rcmod
27	in	IN	26	prep
28	the	DT	30	det
29	third	JJ	30	amod
30	quarter	NN	27	pobj
31	of	IN	30	prep
32	1988	CD	31	pobj
33	,	,	15	punct
34	was	VBD	36	cop
35	the	DT	36	det
36	result	NN	0	root
37	of	IN	36	prep
38	especially	RB	39	advmod
39	strong	JJ	40	amod
40	sales	NNS	37	pobj
41	of	IN	40	prep
42	its	PRP$	44	poss
43	Capoten	NNP	44	nn
44	drug	NN	41	pobj
45	for	IN	44	prep
46	treating	VBG	45	pcomp
47	high	JJ	49	amod
48	blood	NN	49	nn
49	pressure	NN	46	dobj
50	and	CC	49	cc
51	other	JJ	53	amod
52	heart	NN	53	nn
53	disease	NN	49	conj
54	.	.	36	punct

1	The	DT	2	det
2	company	NN	5	nsubjpass
3	was	VBD	5	auxpass
4	officially	RB	5	advmod
5	merged	VBN	0	root
6	with	IN	5	prep
7	Bristol-Myers	NNP	8	nn
8	Co.	NNP	6	pobj
9	earlier	RBR	11	advmod
10	this	DT	11	det
11	month	NN	5	tmod
12	.	.	5	punct

1	Bristol-Myers	NNP	2	nsubj
2	declined	VBD	0	root
3	to	TO	4	aux
4	comment	VB	2	xcomp
5	.	.	2	punct

1	Mr.	NNP	2	nn
2	Riccardo	NNP	6	nsubj
3	of	IN	2	prep
4	Bear	NNP	5	nn
5	Stearns	NNP	3	pobj
6	said	VBD	0	root
7	that	IN	32	complm
8	Schering-Plough	NNP	9	nn
9	Corp.	NNP	13	poss
10	's	POS	9	possessive
11	expected	JJ	13	amod
12	profit	NN	13	nn
13	rise	NN	32	nsubj
14	of	IN	13	prep
15	about	RB	20	quantmod
16	18	CD	20	number
17	%	NN	20	dep
18	to	TO	20	dep
19	20	CD	20	number
20	%	NN	14	pobj
21	,	,	13	punct
22	and	CC	13	cc
23	Bristol-Meyers	NNP	27	poss
24	's	POS	23	possessive
25	expected	JJ	27	amod
26	profit	NN	27	nn
27	increase	NN	13	conj
28	of	IN	27	prep
29	about	RB	30	quantmod
30	13	CD	31	num
31	%	NN	28	pobj
32	are	VBP	6	ccomp
33	largely	RB	40	advmod
34	because	IN	40	dep
35	``	``	40	punct
36	those	DT	37	det
37	companies	NNS	40	nsubjpass
38	are	VBP	40	auxpass
39	really	RB	40	advmod
40	managed	VBN	32	ccomp
41	well	RB	40	advmod
42	.	.	6	punct
43	''	''	6	punct

1	ScheringPlough	NN	2	nsubj
2	earned	VBD	0	root
3	$	$	2	dobj
4	94.4	CD	3	number
5	million	CD	3	number
6	,	,	3	punct
7	or	CC	3	cc
8	84	CD	9	num
9	cents	NNS	3	conj
10	a	DT	11	det
11	share	NN	9	npadvmod
12	,	,	2	punct
13	while	IN	15	mark
14	Bristol-Myers	NNP	15	nsubj
15	earned	VBD	2	advcl
16	$	$	15	dobj
17	232.3	CD	16	number
18	million	CD	16	number
19	,	,	16	punct
20	or	CC	16	cc
21	81	CD	22	num
22	cents	NNS	16	conj
23	a	DT	24	det
24	share	NN	22	npadvmod
25	,	,	15	punct
26	in	IN	15	prep
27	the	DT	29	det
28	like	JJ	29	amod
29	period	NN	26	pobj
30	a	DT	31	det
31	year	NN	32	npadvmod
32	earlier	RBR	29	advmod
33	.	.	2	punct

1	In	IN	10	prep
2	Madison	NNP	1	pobj
3	,	,	2	punct
4	N.J.	NNP	2	appos
5	,	,	10	punct
6	a	DT	7	det
7	spokesman	NN	10	nsubj
8	for	IN	7	prep
9	Schering-Plough	NNP	8	pobj
10	said	VBD	0	root
11	the	DT	12	det
12	company	NN	13	nsubj
13	has	VBZ	10	ccomp
14	``	``	16	punct
15	no	DT	16	det
16	problems	NNS	13	dobj
17	''	''	16	punct
18	with	IN	16	prep
19	the	DT	21	det
20	average	JJ	21	amod
21	estimate	NN	18	pobj
22	by	IN	21	prep
23	a	DT	24	det
24	analysts	NNS	22	pobj
25	that	IN	30	dep
26	third-quarter	JJ	27	amod
27	earnings	NNS	30	nsubj
28	per	IN	27	prep
29	share	NN	28	pobj
30	rose	VBD	21	dep
31	by	IN	30	prep
32	about	RB	33	quantmod
33	19	CD	34	num
34	%	NN	31	pobj
35	,	,	30	punct
36	to	TO	30	prep
37	$	$	36	pobj
38	1	CD	37	num
39	.	.	10	punct

1	The	DT	2	det
2	company	NN	3	nsubj
3	expects	VBZ	25	ccomp
4	to	TO	5	aux
5	achieve	VB	3	xcomp
6	the	DT	9	det
7	20	CD	8	number
8	%	NN	9	amod
9	increase	NN	5	dobj
10	in	IN	9	prep
11	full-year	JJ	12	amod
12	earnings	NNS	10	pobj
13	per	IN	9	prep
14	share	NN	13	pobj
15	,	,	5	punct
16	as	IN	18	mark
17	it	PRP	18	nsubj
18	projected	VBD	5	advcl
19	in	IN	18	prep
20	the	DT	21	det
21	spring	NN	19	pobj
22	,	,	25	punct
23	the	DT	24	det
24	spokesman	NN	25	nsubj
25	said	VBD	0	root
26	.	.	25	punct

1	Meanwhile	RB	4	advmod
2	,	,	4	punct
3	analysts	NNS	4	nsubj
4	said	VBD	0	root
5	Pfizer	NNP	8	poss
6	's	POS	5	possessive
7	recent	JJ	8	amod
8	string	NN	13	nsubj
9	of	IN	8	prep
10	lackluster	JJ	12	amod
11	quarterly	JJ	12	amod
12	performances	NNS	9	pobj
13	continued	VBD	4	ccomp
14	,	,	13	punct
15	as	IN	21	mark
16	earnings	NNS	21	nsubjpass
17	in	IN	16	prep
18	the	DT	19	det
19	quarter	NN	17	pobj
20	were	VBD	21	auxpass
21	expected	VBN	13	advcl
22	to	TO	23	aux
23	decline	VB	21	xcomp
24	by	IN	23	prep
25	about	RB	26	quantmod
26	5	CD	27	num
27	%	NN	24	pobj
28	.	.	4	punct

1	Sales	NNP	21	nsubj
2	of	IN	1	prep
3	Pfizer	NNP	6	poss
4	's	POS	3	possessive
5	important	JJ	6	amod
6	drugs	NNS	2	pobj
7	,	,	6	punct
8	Feldene	NNP	6	appos
9	for	IN	8	prep
10	treating	VBG	9	pcomp
11	arthritis	NN	10	dobj
12	,	,	8	punct
13	and	CC	8	cc
14	Procardia	NNP	8	conj
15	,	,	14	punct
16	a	DT	18	det
17	heart	NN	18	nn
18	medicine	NN	14	appos
19	,	,	14	punct
20	have	VBP	21	aux
21	shrunk	VBN	0	root
22	because	RB	23	advmod
23	of	IN	21	prep
24	increased	JJ	25	amod
25	competition	NN	23	pobj
26	.	.	21	punct

1	``	``	17	punct
2	The	DT	6	det
3	-LRB-	-LRB-	4	punct
4	strong	JJ	6	dep
5	-RRB-	-RRB-	4	punct
6	dollar	NN	7	nsubj
7	hurt	VBD	17	ccomp
8	Pfizer	NNP	7	dobj
9	a	DT	10	det
10	lot	NN	7	npadvmod
11	,	,	7	punct
12	too	RB	7	advmod
13	,	,	17	punct
14	''	''	17	punct
15	Mr.	NNP	16	nn
16	Sweig	NNP	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct

1	In	IN	9	prep
2	the	DT	4	det
3	third	JJ	4	amod
4	quarter	NN	1	pobj
5	last	JJ	6	amod
6	year	NN	9	tmod
7	,	,	9	punct
8	Pfizer	NNP	9	nsubj
9	earned	VBD	0	root
10	$	$	9	dobj
11	216.8	CD	10	number
12	million	CD	10	number
13	,	,	10	punct
14	or	CC	10	cc
15	$	$	10	conj
16	1.29	CD	15	num
17	a	DT	18	det
18	share	NN	15	npadvmod
19	.	.	9	punct

1	In	IN	7	prep
2	New	NNP	3	nn
3	York	NNP	1	pobj
4	,	,	7	punct
5	the	DT	6	det
6	company	NN	7	nsubj
7	declined	VBD	0	root
8	comment	NN	7	dobj
9	.	.	7	punct

1	Analysts	NNS	2	nsubj
2	said	VBD	0	root
3	they	PRP	4	nsubj
4	expected	VBD	2	ccomp
5	Upjohn	NNP	7	poss
6	's	POS	5	possessive
7	profit	NN	10	nsubj
8	to	TO	10	aux
9	be	VB	10	cop
10	flat	JJ	4	xcomp
11	or	CC	10	cc
12	rise	VB	10	conj
13	by	IN	12	prep
14	only	RB	20	quantmod
15	about	RB	20	quantmod
16	2	CD	20	number
17	%	NN	20	dep
18	to	TO	20	dep
19	4	CD	20	number
20	%	NN	13	pobj
21	as	IN	22	mark
22	compared	VBN	20	dep
23	with	IN	22	prep
24	$	$	23	pobj
25	89.6	CD	24	number
26	million	CD	24	number
27	,	,	24	punct
28	or	CC	24	cc
29	49	CD	30	num
30	cents	NNS	24	conj
31	a	DT	32	det
32	share	NN	30	npadvmod
33	,	,	24	punct
34	it	PRP	35	nsubj
35	earned	VBD	24	rcmod
36	a	DT	37	det
37	year	NN	38	npadvmod
38	ago	RB	35	advmod
39	.	.	2	punct

1	Upjohn	NNP	4	poss
2	's	POS	1	possessive
3	biggest-selling	JJ	4	amod
4	drugs	NNS	6	nsubj
5	are	VBP	6	cop
6	Xanax	NNP	0	root
7	,	,	6	punct
8	a	DT	9	det
9	tranquilizer	NN	6	appos
10	,	,	6	punct
11	and	CC	6	cc
12	Halcion	NNP	6	conj
13	,	,	12	punct
14	a	DT	15	det
15	sedative	NN	12	appos
16	.	.	6	punct

1	Sales	NNS	7	nsubjpass
2	of	IN	1	prep
3	both	DT	4	det
4	drugs	NNS	2	pobj
5	have	VBP	7	aux
6	been	VBN	7	auxpass
7	hurt	VBN	0	root
8	by	IN	7	prep
9	new	JJ	11	amod
10	state	NN	11	nn
11	laws	NNS	8	pobj
12	restricting	VBG	11	partmod
13	the	DT	14	det
14	prescriptions	NNS	12	dobj
15	of	IN	14	prep
16	certain	JJ	18	amod
17	tranquilizing	JJ	18	amod
18	medicines	NNS	15	pobj
19	and	CC	11	cc
20	adverse	JJ	21	amod
21	publicity	NN	11	conj
22	about	IN	21	prep
23	the	DT	25	det
24	excessive	JJ	25	amod
25	use	NN	22	pobj
26	of	IN	25	prep
27	the	DT	28	det
28	drugs	NNS	26	pobj
29	.	.	7	punct

1	Also	RB	12	advmod
2	,	,	12	punct
3	the	DT	4	det
4	company	NN	7	poss
5	's	POS	4	possessive
6	hair-growing	JJ	7	amod
7	drug	NN	12	nsubj
8	,	,	7	punct
9	Rogaine	NNP	7	appos
10	,	,	7	punct
11	is	VBZ	12	aux
12	selling	VBG	47	ccomp
13	well	RB	12	advmod
14	--	:	12	punct
15	at	IN	12	prep
16	about	RB	17	quantmod
17	$	$	15	pobj
18	125	CD	17	number
19	million	CD	17	number
20	for	IN	17	prep
21	the	DT	22	det
22	year	NN	20	pobj
23	,	,	12	punct
24	but	CC	12	cc
25	the	DT	26	det
26	company	NN	28	poss
27	's	POS	26	possessive
28	profit	NN	34	nsubjpass
29	from	IN	28	prep
30	the	DT	31	det
31	drug	NN	29	pobj
32	has	VBZ	34	aux
33	been	VBN	34	auxpass
34	reduced	VBN	12	conj
35	by	IN	34	prep
36	Upjohn	NNP	42	poss
37	's	POS	36	possessive
38	expensive	JJ	42	amod
39	print	NN	42	nn
40	and	CC	39	cc
41	television	NN	39	conj
42	campaigns	NNS	35	pobj
43	for	IN	42	prep
44	advertising	VBG	43	pobj
45	,	,	47	punct
46	analysts	NNS	47	nsubj
47	said	VBD	0	root
48	.	.	47	punct

1	In	IN	7	prep
2	Kalamazoo	NNP	1	pobj
3	,	,	2	punct
4	Mich.	NNP	2	appos
5	,	,	2	punct
6	Upjohn	NNP	7	nsubj
7	declined	VBD	0	root
8	comment	NN	7	dobj
9	.	.	7	punct


